Description: In this webcast, we will speak with actuarial leaders who developed their personal brand over several years to better understand just how powerful having a personal brand can be in actuarial work.

Description: Mortality Model Selection and Combination in RAlternative approaches for selecting mortality models and forecasting mortality have been proposed. The usual practice is to base mortality forecasts on a single mortality model selected using in-sample goodness-of-fit measures. However, cross-validation and other alternative out-of-sample measures are increasingly being used in model selection, and model combination methods are becoming a common alternative to using a single mortality model. Such methods combine predictions from multiple mortality models to reduce model choice uncertainty and improve forecast accuracy. Explore techniques to select and combine mortality models using the freely available open source R package CoMoMo (https://github.com/kessysalvatory/CoMoMo), which extends the widely used R package StMoMo (https://CRAN.R-project.org/package=StMoMo). We will use data for the USA and other countries to discuss and demonstrate four different model combination approaches including simple model averaging, Bayesian model averaging, model confidence set, and stacked regression ensembles.

Description: "Living to 100 in the time of COVID-19: A Study of Late –Life Mortality Trajectories, Leonid A. Gavrilov, Ph.D., Natalia S. Gavrilova, Ph.D., Academic Research Centers, NORC at the University of Chicago Swedish Mortality Does Not Decelerate in Recent Cohorts, or Does it? – Roland Rau, Ph. D., Professor, University of Rostock & Max Planck Institute for Demographic Research, Rostock, Germany; Marcus Ebeling, Ph.D., Karin Modig, Ph.D., Associate Professor, Anders Ahlbom, Ph.D., Professor Emeritus, Karolinska Institute, Stockholm Sweden; Kai Kaufhold, Aktuar DAV, Ad Res Advanced Reinsurance Services GmbH, Cologne, Germany; Annika Ziegler, Lukas Stake, Hochschule Koblenz & Ad Res, Germany"

Description: "How long is long in longevity? – Jesús-Adrian Álvarez, Ph.D. - Danish Labour Market Supplementary Pension Fund (ATP), The Rate of Aging in humans is constant. New evidence – Marcus Ebeling, PhD., Research Group Mathematical and Actuarial Demography, Max Planck Institute for Demographic Research, Rostock, Germany, Department of Sociology and Demography, University of Rostock, Rostock, Germany; Roland Rau, Ph.D., Professor, Research Group Mathematical and Actuarial Demography, Max Planck Institute for Demographic Research, Rostock, Germany, C6 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Håkan Malmström, Ph.D., C6 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Anders Ahlbom, Ph.D., Professor Emeritus, Karen Modig, Ph.D., Associate Professor, C6 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden Human Lifetimes: Finite But Not Necessarily Bounded – Fei Huang, PhD., School of Risk & Actuarial Studies, UNSW Sydney; Ross Maller, Ph.D., Emeritus Professor, Xu Ning, Ph.D., Research School of Finance, Actuarial Studies & Statistics, Australian National University, Brandon Milholland, Ph.D., IQVIA Plymouth Meeting, PA."

Description: "Minimum Social Security Benefit (s) and the Alone Stage of Retirement in the U.S.? – Lori J. Curtis, PhD., Douglas Andrews, FSA, FCIA, Ph.D., University of Waterloo The Importance of Cognitive Health – Gordon Woo,Ph.D., RMS LifeRisks"

Description: "Driving Longevity Through Educational Attainment – Robert L. Brown – Ph. D. Higher Age U.S. Mortality By Education and Cause of Death Trends, Inequality and Controllable Risk Factors – Andrew J. G. Cairns – MPA Ph.D., Maxwell Institute for Mathematical Sciences, and Department of Actuarial Mathematics and Statistics, Heriot-Watt University, Edinburgh, Scotland, UK, Cristian Redondo Lour´es, Ph.D., Actuarial Solutions,"

Description: Actuarial funding of OPEB plans is primarily a public sector phenomenon due to the different regulations and tax laws that impact private sector organizations in the US. OPEB funding started to gain momentum with the implementation of GASB Statement 45 in the mid to late 2000s.

Description: Explore the value and cost of prescription drugs, how they should be defined and measured and the effects various stakeholders in the pharmacy ecosystem can have on these factors in the latest webcast. You'll investigate the impact of coverage, formulary and rebate negotiations and related benefit design. Find out how actuaries can answer questions related to the prescription drug industry, in addition to improving the access, quality and affordability of prescription drugs in the United States. Join us for this webcast and come learn about value-based contract design, negotiations, implementation and administration for prescription drugs.

Description: Keynote Speaker: J.D. Kleinke, Author and Medical Economist J.D. Kleinke has been instrumental in the creation of four health care information organizations; has served on the Boards of several health care companies; and spent many years advising both sides of the political aisle on non-partisan, practical approaches to health policy and legislation.

Description: Learn from panelists from different companies as they come together to discuss their experiences.